Neurology and Neurosurgery

145-160 of 433

• 

  RestartResume

  Clinical Conundrums in ARIA: Triage and Imaging in the Emergency Setting for Patients Prescribed Anti-Aβ mAbs

  RestartResume

  Clinical Conundrums in ARIA: Triage and Imaging in the Emergency Setting for Patients Prescribed Anti-Aβ mAbs

  MinuteCE®

  Clinical Conundrums in ARIA: Triage and Imaging in the Emergency Setting for Patients Prescribed Anti-Aβ mAbs

  1.25 program credits

  • 

    

    James R. Bateman, MD, MPH

  • 

    

    Danya Khoujah, MBBS, MEHP, FACEP, FAAEM

  • 

    

    Jerome A. Barakos, MD

  1.25 program credits

• 

  RestartResume

  Clinical Conundrums in ARIA: Differentiating and Navigating ARIA vs Stroke When an Emergent MRI is Unavailable

  RestartResume

  Clinical Conundrums in ARIA: Differentiating and Navigating ARIA vs Stroke When an Emergent MRI is Unavailable

  MinuteCE®

  Clinical Conundrums in ARIA: Differentiating and Navigating ARIA vs Stroke When an Emergent MRI is Unavailable

  1.25 program credits

  • 

    

    James R. Bateman, MD, MPH

  • 

    

    Jerome A. Barakos, MD

  • 

    

    Danya Khoujah, MBBS, MEHP, FACEP, FAAEM

  1.25 program credits

• 

  RestartResume

  Clinical Conundrums in ARIA: How to Manage Severe ARIA

  RestartResume

  Clinical Conundrums in ARIA: How to Manage Severe ARIA

  MinuteCE®

  Clinical Conundrums in ARIA: How to Manage Severe ARIA

  1.25 program credits

  • 

    

    James R. Bateman, MD, MPH

  • 

    

    Danya Khoujah, MBBS, MEHP, FACEP, FAAEM

  • 

    

    B. Joy Snider, MD, PhD

  1.25 program credits

• 

  RestartResume

  Monitoring Multiple Sclerosis: The Role of Serum Neurofilament Light Chain Levels

  RestartResume

  Monitoring Multiple Sclerosis: The Role of Serum Neurofilament Light Chain Levels

  NeuroFrontiers

  Monitoring Multiple Sclerosis: The Role of Serum Neurofilament Light Chain Levels

• 

  RestartResume

  Engineering Autoimmunity: A New Model for Studying MS Progression and Remyelination

  RestartResume

  Engineering Autoimmunity: A New Model for Studying MS Progression and Remyelination

  NeuroFrontiers

  Engineering Autoimmunity: A New Model for Studying MS Progression and Remyelination

  • 

    

    Christian Cordano, MD, PhD

• 

  RestartResume

  Advances in MS Management: Current and Future Directions

  RestartResume

  Advances in MS Management: Current and Future Directions

  NeuroFrontiers

  Advances in MS Management: Current and Future Directions

• 

  RestartResume

  Diagnosing Duchenne Muscular Dystrophy: Recognizing Signs and Reducing Delays

  RestartResume

  Diagnosing Duchenne Muscular Dystrophy: Recognizing Signs and Reducing Delays

  NeuroFrontiers

  Diagnosing Duchenne Muscular Dystrophy: Recognizing Signs and Reducing Delays

  • 

    

    Nancy Kuntz, MD

• 

  RestartResume

  Duchenne Muscular Dystrophy Management: Analyzing Current Approaches

  RestartResume

  Duchenne Muscular Dystrophy Management: Analyzing Current Approaches

  NeuroFrontiers

  Duchenne Muscular Dystrophy Management: Analyzing Current Approaches

  • 

    

    Nancy Kuntz, MD

• 

  RestartResume

  From Trials to Practice: Evaluating Xanomeline-Trospium Chloride for Schizophrenia 

  RestartResume

  From Trials to Practice: Evaluating Xanomeline-Trospium Chloride for Schizophrenia 

  NeuroFrontiers

  From Trials to Practice: Evaluating Xanomeline-Trospium Chloride for Schizophrenia 

  • 

    

    Ashley Baker, MSN, PMHNP

  • 

    

    Steven Paul, MD

• 

  RestartResume

  Exploring Metabolomics in Multiple Sclerosis

  RestartResume

  Exploring Metabolomics in Multiple Sclerosis

  NeuroFrontiers

  Exploring Metabolomics in Multiple Sclerosis

  • 

    

    Pavan Barghava, MD

• 

  RestartResume

  Metabolomics in Multiple Sclerosis: Advancing Diagnosis, Prognosis, and Treatment Response

  RestartResume

  Metabolomics in Multiple Sclerosis: Advancing Diagnosis, Prognosis, and Treatment Response

  NeuroFrontiers

  Metabolomics in Multiple Sclerosis: Advancing Diagnosis, Prognosis, and Treatment Response

  • 

    

    Pavan Barghava, MD

• 

  RestartResume

  Safety Outcomes in MS Clinical Trials: Examining Comorbidities and Adverse Events

  RestartResume

  Safety Outcomes in MS Clinical Trials: Examining Comorbidities and Adverse Events

  NeuroFrontiers

  Safety Outcomes in MS Clinical Trials: Examining Comorbidities and Adverse Events

  • 

    

    Amber Salter, PhD

• 

  RestartResume

  MS and the Ketogenic Diet: Potential Impacts on Inflammation and Relapse

  RestartResume

  MS and the Ketogenic Diet: Potential Impacts on Inflammation and Relapse

  NeuroFrontiers

  MS and the Ketogenic Diet: Potential Impacts on Inflammation and Relapse

  • 

    

    Michael Kornberg, MD, PhD

• 

  RestartResume

  Managing Multiple Sclerosis: The Impact of Dietary Modifications

  RestartResume

  Managing Multiple Sclerosis: The Impact of Dietary Modifications

  On the Frontlines of Multiple Sclerosis

  Managing Multiple Sclerosis: The Impact of Dietary Modifications

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Anna A. Shah, MD

• 

  RestartResume

  Strategies and Considerations for Managing MS in Pregnant Women

  RestartResume

  Strategies and Considerations for Managing MS in Pregnant Women

  On the Frontlines of Multiple Sclerosis

  Strategies and Considerations for Managing MS in Pregnant Women

  • 

    

    Charles Turck, PharmD, BCPS, BCCCP

  • 

    

    Anna A. Shah, MD

• 

  RestartResume

  Cognitive Impairment in MS: Mitigating Impacts to Optimize Brain Health

  RestartResume

  Cognitive Impairment in MS: Mitigating Impacts to Optimize Brain Health

  NeuroFrontiers

  Cognitive Impairment in MS: Mitigating Impacts to Optimize Brain Health

  • 

    

    Christopher Lock, MD

• Previous
• 1
• 2
• …
• 8
• 9
• 10
• 11
• 12
• …
• 27
• 28
• Next